Nichi-Iko Delays US Infliximab Amid Coronavirus Outbreak
As Japanese Company Trains Focus On Bevacizumab
Nichi-Iko maintains it is still on course to be one of the very few players to offer an ‘interchangeable’ biosimilar in the US, with its rival to Janssen’s Remicade. The Japanese company has revealed its latest schedule as it also reported full-year financial results.
